Vascular Biology |
From the Departments of Cardiology and Vascular Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Correspondence to Toyoaki Murohara, MD, PhD, FAHA, Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550 Japan. E-mail murohara{at}med.nagoya-u.ac.jp
Objective In vivo administration of granulocyte colony-stimulating factor (G-CSF) has been shown to facilitate regeneration of cardiovascular tissues. However, G-CSF causes marked leukocytosis that potentially induces adverse cardiovascular events. Earlier studies showed that G-CSF had direct stimulatory actions on mature endothelial cells, resulting in promotion of angiogenesis. We thus examined whether low doses of recombinant human G-CSF (rhG-CSF) locally injected into ischemic tissues would stimulate angiogenesis without inducing severe leukocytosis.
Methods and Results Reverse-transcription polymerase chain reaction (PCR) revealed expression of G-CSF receptor in human umbilical vein endothelial cells (HUVECs). rhG-CSF (100 ng/mL) enhanced migration and tube formation but not proliferation of HUVECs in vitro. We then examined the effects of rhG-CSF on angiogenesis in a rat model of hindlimb ischemia. Nude rats received in their ischemic skeletal muscles either rhG-CSF (2, 10, 20 µg/kg per day) or saline (control) for 6 days. Laser Doppler blood flowmetry (LDBF) revealed an augmented ischemic/normal limb LDBF ratio and an increased capillary density in the rhG-CSFtreated groups compared with the control at days 14, 21, and 28 (P<0.05). These doses of rhG-CSF induced only mild leukocytosis (
1.4-fold increases versus baseline).
Conclusions rhG-CSF promoted endothelial migration and tube formation in vitro. Local injection of low doses rhG-CSF effectively augmented ischemia-induced angiogenesis in vivo. This treatment regimen of low-dose rhG-CSF may become a new and safe modality for therapeutic angiogenesis.
G-CSF receptor was expressed in human umbilical vein endothelial cells (HUVECs). rhG-CSF (100 ng/mL) enhanced migration and tube formation but not proliferation of HUVECs. Moreover, local injection of low doses rhG-CSF augmented ischemia-induced angiogenesis in vivo. This treatment regimen of low-dose rhG-CSF may become a new and safe modality for therapeutic angiogenesis.
Key Words: angiogenesis endothelial cell ischemia rhG-CSF
This article has been cited by other articles:
![]() |
H. Okada, G. Takemura, K.-i. Kosai, A. Tsujimoto, M. Esaki, T. Takahashi, S. Nagano, H. Kanamori, S. Miyata, Y. Li, et al. Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H616 - H626. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hazarika, M. Angelo, Y. Li, A. J. Aldrich, S. I. Odronic, Z. Yan, J. S. Stamler, and B. H. Annex Myocyte Specific Overexpression of Myoglobin Impairs Angiogenesis After Hind-Limb Ischemia Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2144 - 2150. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iohara, L. Zheng, H. Wake, M. Ito, J. Nabekura, H. Wakita, H. Nakamura, T. Into, K. Matsushita, and M. Nakashima A Novel Stem Cell Source for Vasculogenesis in Ischemia: Subfraction of Side Population Cells from Dental Pulp Stem Cells, September 1, 2008; 26(9): 2408 - 2418. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sugiura, T. Kondo, Y. Kureishi-Bando, Y. Numaguchi, O. Yoshida, Y. Dohi, G. Kimura, R. Ueda, T. J. Rabelink, and T. Murohara Nifedipine Improves Endothelial Function: Role of Endothelial Progenitor Cells Hypertension, September 1, 2008; 52(3): 491 - 498. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |